Tirzepatide (Mounjaro)
GLP-1 + GIP agonist · GLP-1 class · sc weekly · Eli Lilly
Top dose
15 mg
HbA1c reduction
-2.46%
at week 40 · efficacy
AE discontinuation
8.6%
Status
approved
Pivotal trial
- Trial
- SURPASS-2
- Indication
- type 2 diabetes
- Duration
- 40 weeks
- ClinicalTrials.gov
- NCT03987919
- Sponsor
- Eli Lilly
Notes
SURPASS-2 (Frias NEJM 2021) head-to-head vs semaglutide 1 mg: tirzepatide 15 mg HbA1c -2.46% (efficacy estimand) vs semaglutide -1.86%, baseline 8.28%. The deepest HbA1c reduction of any approved incretin.